Figure S1 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity

Figure S1 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity

<p>Figure S1</p>

Պահպանված է:

Մատենագիտական մանրամասներ
Հիմնական հեղինակ:	Shiyi Yu (17079079) (author)
Այլ հեղինակներ:	Ying Wang (17079082) (author), Xue Gong (17079085) (author), Zhehao Fan (17079088) (author), Zheng Wang (17079091) (author), Zhengyan Liang (17079094) (author), Rui Wu (17079097) (author), Binjie Cao (17079100) (author), Ning Wang (17079103) (author), Caili Bi (17079106) (author), Dan Lv (17079109) (author), Haibo Sun (17079112) (author)
Հրապարակվել է:	2025
Խորագրեր:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Breast Cancer Cell Cycle Signal transduction pathways Drug Resistance Regulation of gene expression in drug resistance Endocrine-Related Cancers
Ցուցիչներ:	Ավելացրեք ցուցիչ Չկան պիտակներ, Եղեք առաջինը, ով նշում է այս գրառումը!

Նմանատիպ նյութեր

Figure S2 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
‌: Shiyi Yu (17079079)
Հրապարակվել է: (2025)

Figure S3 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
‌: Shiyi Yu (17079079)
Հրապարակվել է: (2025)

Figure S4 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
‌: Shiyi Yu (17079079)
Հրապարակվել է: (2025)

Figure S5 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
‌: Shiyi Yu (17079079)
Հրապարակվել է: (2025)

Figure S6 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
‌: Shiyi Yu (17079079)
Հրապարակվել է: (2025)

Figure S7 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
‌: Shiyi Yu (17079079)
Հրապարակվել է: (2025)

Figure S8 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
‌: Shiyi Yu (17079079)
Հրապարակվել է: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
‌: Yufang Bao (15386826)
Հրապարակվել է: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
‌: Yufang Bao (15386826)
Հրապարակվել է: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
‌: Yufang Bao (15386826)
Հրապարակվել է: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
‌: Yufang Bao (15386826)
Հրապարակվել է: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
‌: Yufang Bao (15386826)
Հրապարակվել է: (2025)

Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
‌: Nicole A. Traphagen (16677391)
Հրապարակվել է: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
‌: Alex C.H. Liu (14961921)
Հրապարակվել է: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
‌: Alex C.H. Liu (14961921)
Հրապարակվել է: (2025)

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
‌: Seung Yeon Oh (15051017)
Հրապարակվել է: (2025)

Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
‌: Seung Yeon Oh (15051017)
Հրապարակվել է: (2025)

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer
‌: Jiachun Su (16990970)
Հրապարակվել է: (2025)

Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
‌: Nicole A. Traphagen (16677391)
Հրապարակվել է: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
‌: Alex C.H. Liu (14961921)
Հրապարակվել է: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
‌: Alex C.H. Liu (14961921)
Հրապարակվել է: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
‌: Alex C.H. Liu (14961921)
Հրապարակվել է: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
‌: Alex C.H. Liu (14961921)
Հրապարակվել է: (2025)

Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
‌: Seung Yeon Oh (15051017)
Հրապարակվել է: (2025)

Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
‌: Seung Yeon Oh (15051017)
Հրապարակվել է: (2025)

Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
‌: Seung Yeon Oh (15051017)
Հրապարակվել է: (2025)

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
‌: Seung Yeon Oh (15051017)
Հրապարակվել է: (2025)

Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
‌: Seung Yeon Oh (15051017)
Հրապարակվել է: (2025)

Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
‌: Seung Yeon Oh (15051017)
Հրապարակվել է: (2025)

Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
‌: Seung Yeon Oh (15051017)
Հրապարակվել է: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
‌: Seung Yeon Oh (15051017)
Հրապարակվել է: (2025)

Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
‌: Seung Yeon Oh (15051017)
Հրապարակվել է: (2025)

Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
‌: Seung Yeon Oh (15051017)
Հրապարակվել է: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
‌: Dahihm Kim (16546203)
Հրապարակվել է: (2025)

Table S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
‌: Dahihm Kim (16546203)
Հրապարակվել է: (2025)

Supplementary Table S1 from Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma
‌: Phyllis S.Y. Chong (17141520)
Հրապարակվել է: (2025)

Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
‌: Ossia M. Eichhoff (14964145)
Հրապարակվել է: (2025)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
‌: Niklas Klümper (15048887)
Հրապարակվել է: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
‌: Dahihm Kim (16546203)
Հրապարակվել է: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
‌: Dahihm Kim (16546203)
Հրապարակվել է: (2025)

Cannot write session to /tmp/vufind_sessions/sess_q3q7mq78ftdfib2sedc66ns249